Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a…
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted…
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing…
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…
EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and…
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatmentsLEHI,…
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at…
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded…
New panel will enable rapid, precise genetic profiling of patients with deadly diseaseNEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE)…
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…